Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI read tumor slides to outsmart childhood cancer?

NCT ID NCT06822842

Diagnosis Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing whether an artificial intelligence (AI) model can accurately diagnose and grade several types of solid tumors that affect children, including neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. The AI is trained on thousands of pathology images and medical knowledge to identify tumor regions, detect cancer, and classify subtypes. The goal is to provide a reliable, consistent tool that supports pathologists in making faster and more precise diagnoses, potentially leading to better personalized treatment for children with these cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An artificial intelligence (AI) model that analyzes pathology images to diagnose and grade pediatric solid tumors
What this could lead to
If successful, this AI tool could help doctors diagnose and grade pediatric solid tumors more accurately and consistently, even where expert pathologists are scarce, potentially improving treatment decisions.
What could go wrong
The AI model is still in testing and may not perform accurately across all tumor types or in real-world settings. Its success depends on the quality of the training data and may not generalize beyond the study's scope.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,229 people

The number who actually took part.

Started

Jan 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The clinical data and HE-stained sections of pathological tissues of children with solid tumors (including neuroblastoma, Wilms tumor, hepatoblastoma and medulloblastoma, etc.) diagnosed and treated by histopathology in Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine from January 2012 to January 2022 were retrospectively analyzed.

Ages

0 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Neuroblastoma (NB): For newly diagnosed patients with NB aged 0-18 years, the diagnosis criteria are one of the following two items: (1) the patient's tumor tissue has obtained a positive pathological diagnosis under the light microscope; (2) Bone marrow biopsy or aspiration revealed characteristic neuroblastoma cells, which were small round cells, arranged in a nested or chrysanthemum clump or positive staining for anti-GD2 antibodies, and accompanied by an increase in urinary vanillylmandelic acid (VMA) and an increase in blood neuron-specific enolase (NSE). 2. Wilms tumor (nephroblastoma): patients aged 0-18 years old who have been diagnosed with Wilms tumor by histopathology. 3. Hepatoblastoma (HB): Patients aged 0-18 years who have been diagnosed with hepatoblastoma by histopathology. 4. Medulloblastoma (MB): Patients aged 0-18 years with a confirmed histopathological diagnosis of medulloblastoma. 5. rhabdomyosarcoma (RMS): patients aged 0-18 years old who have been diagnosed with medulloblastoma by histopathology. Exclusion Criteria: 1. The patient's medical record and treatment follow-up information are incomplete; HE is not stained or faded 2. Those who have 2 or more types of tumors at the same time; 3. Those who do not meet the enrollment criteria. 4. Tumor subtype with less than 3 WSI images

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatoblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease hepatoblastoma medulloblastoma neuroblastoma rhabdomyosarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatoblastoma Medulloblastoma Neuroblastoma Rhabdomyosarcoma Wilms tumor

Contacts and locations

Locations

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200092, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.